STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline

Rhea-AI Summary
Merck (MRK) initiates pivotal Phase 3 trials for four investigational candidates in hematologic malignancies and solid tumors, including bomedemstat, nemtabrutinib, MK-2870, and MK-5684. The trials demonstrate the company's commitment to research across novel mechanisms of action in various cancers, such as lung, endometrial, and prostate cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
clinical trial
-
News

Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Merck (NYSE: MRK) announced the participation of Robert M. Davis and Dr. Dean Y. Li in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024. The event will be live webcasted for investors, analysts, media, and the general public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences
-
News

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Rhea-AI Summary
Daiichi Sankyo (4568) and Merck (MRK) announce FDA Priority Review for patritumab deruxtecan (HER3-DXd) for EGFR-mutated non-small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
News

Merck Provides U.S. Regulatory Update on Gefapixant

Rhea-AI Summary
Merck (MRK) receives Complete Response Letter from FDA for gefapixant NDA, citing lack of substantial evidence for effectiveness in treating refractory chronic cough (RCC) and unexplained chronic cough (UCC) in adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
News

Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference

Rhea-AI Summary
Merck (NYSE: MRK) CEO to participate in fireside chat at Goldman Sachs Healthcare C-Suite Unscripted Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
conferences
-
News

FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults

Rhea-AI Summary
Merck (MRK) announces FDA acceptance for priority review of V116, a 21-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
News

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer

Rhea-AI Summary
Merck (MRK) has received approval from the European Commission for two new indications for KEYTRUDA, their anti-PD-1 therapy, in gastrointestinal cancers. The approvals are based on positive Phase 3 trial results from KEYNOTE-859 and KEYNOTE-966, showing significant improvement in overall survival rates. These approvals bring the total number of KEYTRUDA indications in the EU to 26, with seven in gastrointestinal cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
News

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

Rhea-AI Summary
Merck (MRK) has received FDA approval for KEYTRUDA, its anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv), for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The approval is based on the results of the Phase 3 KEYNOTE-A39 trial, demonstrating a superior overall survival benefit with KEYTRUDA plus Padcev versus platinum-based chemotherapy. The approval expands the use of KEYTRUDA plus Padcev for locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility. The approval came nearly five months ahead of the PDUFA goal date of May 9, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
fda approval
-
News

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI

Rhea-AI Summary
Merck (MRK) receives FDA approval for WELIREG, the first HIF-2α inhibitor for advanced RCC patients. The approval is based on statistically significant results from LITESPARK-005, demonstrating superior progression-free survival and objective response rate compared to everolimus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
fda approval
News

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years

Rhea-AI Summary
Moderna, Inc. (MRNA) and Merck (MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, showing that mRNA-4157 in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection. The companies have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.16 as of November 25, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 256.1B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#34 Ranked by Market Cap
#933 Ranked by Dividends

MRK Stock Data

256.11B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH